| Biomarker ID | 44 |
| PMID | 12939396 |
| Year | 2003 |
| Biomarker | Fatty Acid Synthase (FAS) |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Metastatic PCa (12 fold) [Mean Value: GS7 :149.2 Vs Metastatic: 1960.8] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Ghrelin pathway,Fatty acyl-CoA biosynthesis,Fatty acid biosynthesis,SREBF and miR-33 in cholesterol and lipid homeostasis,Triglyceride biosynthesis |
| Experiment | Gleason Score 7 Vs Metastatic Tumor |
| Type of Biomarker | Prognostic |
| Cohort | 59 patients (52 primaries and 7 metastases) were selected for analysis. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.00000029 |
| Method Used | oligonucleotide arrays and tissue microarrays (TMA) |
| Clinical | No |
| Remarks | Analysis done on FAS mRNA and Protein |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | FASN |